Company:  AVEO PHARMACEUTICALS INC (AVEO)
Form Type:  10-K
Filing Date:  3/11/2013 
CIK:  0001325879 
Address:  650 E. KENDALL STREET 
City, State, Zip:  CAMBRIDGE, Massachusetts 02142 
Telephone:  (617) 299-5000 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$1.12  
Change: 
0.01 (0.90%)  
Trade Time: 
Oct 01  
Market Cap: 
$58.57M
Description of Business
We are a biopharmaceutical company committed to discovering and developing targeted therapies designed to provide substantial impact in the lives of people with cancer by addressing unmet medical needs. AVEO�s proprietary Human Response Platform� provides the company unique insights into cancer and related disease biology and is being leveraged in the discovery and clinical development of its therapeutic candidates. Some of the programs we are developing include: � AV-203: AV-203 is an anti-ErbB3 monoclonal antibody with broad therapeutic potential. AV-203 has high ErbB3 affinity and potent anti-tumor activity in mouse models. AV-203 inhibits the activity of the ErbB3 receptor and our preclinical studies suggest that neuregulin-1, or NRG1, levels predict AV-203 anti-tumor activity in preclinical models.
Register for EDGAR Pro and access this filing in:     
  FORM 10-K
    PART I
      ITEM 1. Business
      Legal Proceedings
      Item 1A. Risk Factors
      ITEM 1B. Unresolved Staff Comments
      ITEM 2. Properties
      ITEM 4. Mine Safety Disclosures
    PART II
      ITEM 5. Market for Registrant's Common Equity, Related ...
      ITEM 6. Selected Financial Data
      ITEM 7. Management's Discussion and Analysis of Financial ...
        Results of Operations
        Liquidity and Capital Resources
      ITEM 7A. Quantitative and Qualitative Disclosures About ...
      ITEM 8. Financial Statements and Supplementary Data
        REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
        BALANCE SHEET
        INCOME STATEMENT
        STOCKHOLDERS EQUITY
        CASH FLOW
        Notes to Consolidated Financial Statements
      ITEM 9. Changes in and Disagreements with Accountants on ...
      ITEM 9A. Controls and Procedures
      REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
      ITEM 9B. Other Information
    PART III
      ITEM 10. Directors, Executive Officers and Corporate Governance
      ITEM 11. Executive Compensation
      ITEM 12. Security Ownership of Certain Beneficial Owners and ...
      ITEM 13. Certain Relationships and Related Person ...
      ITEM 14. Principal Accounting Fees and Services
    PART IV
      ITEM 15. Exhibits and Financial Statement Schedules
    Report of Independent Registered Public Accounting Firm
    SIGNATURES
    Exhibit Index
  EXHIBIT 10.18
  EXHIBIT 10.19
  EXHIBIT 21.1
  EXHIBIT 23.1
    Consent of Independent Registered Public Accounting Firm
  EXHIBIT 31.1
    CERTIFICATION
  EXHIBIT 31.2
    CERTIFICATION
  EXHIBIT 32.1
    CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
  EXHIBIT 32.2
    CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
BROKERAGE PARTNERS